GlaxoSmithKline is taking a gamble on Idera Pharmaceuticals' antisense drug technology, promising up to $100 million in a collaboration focused on renal disease.
Médecins Sans Frontières, a global charity and frequent pharma critic, has initiated a worldwide petition calling for Pfizer and GlaxoSmithKline to reduce the prices of their pneumonia vaccines to $5 per child--for all three doses--in emerging markets and for humanitarian organizations.
GlaxoSmithKline's experimental Ebola jab, which was taken to Phase I in the U.S. and Mali last October, was well-tolerated and elicited strong immune responses in adults.
Bestselling asthma drugs from Novartis and respiratory behemoth GlaxoSmithKline are also showing more adverse events in post-marketing safety data than competing products from Merck, according to a new report, potentially presenting issues further down the line as companies duke it out for market share.
Throughout the tough times faced by the British biopharma industry, the country could always point to its scientific excellence as a source of pride. Now, with more money swilling around, the sector should be enjoying better days, yet as financial woes have receded another resource shortage has come into view: The United Kingdom appears to be running low on scientists.
GlaxoSmithKline has a vision for its respiratory unit that looks not unlike the portfolio approach some diabetes drugmakers have taken, with a range of therapies for different disease stages and different types of patients. And last week, the FDA approval of an add-on treatment for a subset of severe asthma patients brought it one step closer to achieving that vision.
For years, Merck and GlaxoSmithKline have battled safety worries and other stigmas with their HPV vaccines. But this week, the companies received a piece of positive news from the European Medicines Agency, which reported that a committee found no link between the shots and two rare conditions it had been studying.
AstraZeneca says it has a prime late-stage drug contender in the clinic that has the potential to compete for the lupus market. But it is lining up against GlaxoSmithKline, which has been touting promising Phase III data this week for a new subcutaneous formulation of Benlysta, a drug that has frequently disappointed analysts who have been tracking its sales over the years.
GlaxoSmithKline secured FDA approval for Nucala, an injectable treatment for asthma, a therapeutic dominated by inhaled drugs. Still, the alternative form of drug delivery for respiratory conditions has the potential to reach sales of $7 billion a year, according to analysts.
Partners GlaxoSmithKline and Avalon Ventures have seeded a 7th startup in their company-building collaboration, lining up $10 million for a new effort to treat ALS.